Skeletal muscle morphology in sarcopenia defined using the EWGSOP criteria: findings from the Hertfordshire Sarcopenia Study (HSS)

por Patel, H. P., White, M. C., Westbury, L., Syddall, H. E., Stephens, P. J., Clough, G. F., Cooper, C., Sayer, A. A.
Publicado 2015

Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer

por Ross, J S, Wang, K, Elkadi, O R, Tarasen, A, Foulke, L, Sheehan, C E, Otto, G A, Palmer, G, Yelensky, R, Lipson, D, Chmielecki, J, Ali, S M, Elvin, J, Morosini, D, Miller, V A, Stephens, P J
Publicado 2014

Inhibiting MEK in MAPK pathway-activated myeloma

por Heuck, C J, Jethava, Y, Khan, R, van Rhee, F, Zangari, M, Chavan, S, Robbins, K, Miller, S E, Matin, A, Mohan, M, Ali, S M, Stephens, P J, Ross, J S, Miller, V A, Davies, F, Barlogie, B, Morgan, G
Publicado 2016

Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer

por Sokol, E S, Feng, Y X, Jin, D X, Basudan, A, Lee, A V, Atkinson, J M, Chen, J, Stephens, P J, Frampton, G M, Gupta, P B, Ross, J S, Chung, J H, Oesterreich, S, Ali, S M, Hartmaier, R J
Publicado 2019

Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies

por Ross, J. S., Gay, L. M., Wang, K., Vergilio, J.-A., Suh, J., Ramkissoon, S., Somerset, H., Johnson, J. M., Russell, J., Ali, S., Schrock, A. B., Fabrizio, D., Frampton, G., Miller, V., Stephens, P. J., Elvin, J. A., Bowles, D. W.
Publicado 2017

Comprehensive genomic profiling identifies a novel TNKS2–PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy

por Chalmers, Z R, Ali, S M, Ohgami, R S, Campregher, P V, Frampton, G M, Yelensky, R, Elvin, J A, Palma, N A, Erlich, R, Vergilio, J-A, Chmielecki, J, Ross, J S, Stephens, P J, Hermann, R, Miller, V A, Miles, C R
Publicado 2015

Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies

por Ross, J S, Wang, K, Rand, J V, Gay, L, Presta, M J, Sheehan, C E, Ali, S M, Elvin, J A, Labrecque, E, Hiemstra, C, Buell, J, Otto, G A, Yelensky, R, Lipson, D, Morosini, D, Chmielecki, J, Miller, V A, Stephens, P J
Publicado 2014

Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer

por Vaishnavi, A., Capelletti, M., Le, A.T., Kako, S., Butaney, M., Ercan, D., Mahale, S., Davies, K.D., Aisner, D.L., Pilling, A.B., Berge, E.M., Kim, J., Sasaki, H., Park, S., Kryukov, G., Garraway, L.A., Hammerman, Peter S., Haas, J., Andrews, S.W., Lipson, D., Stephens, P.J., Miller, V.A., Varella-Garcia, M., Jänne, P.A., Doebele, R.C.
Publicado 2013

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer

por Chung, J H, Pavlick, D, Hartmaier, R, Schrock, A B, Young, L, Forcier, B, Ye, P, Levin, M K, Goldberg, M, Burris, H, Gay, L M, Hoffman, A D, Stephens, P J, Frampton, G M, Lipson, D M, Nguyen, D M, Ganesan, S, Park, B H, Vahdat, L T, Leyland-Jones, B, Mughal, T I, Pusztai, L, O’Shaughnessy, J, Miller, V A, Ross, J S, Ali, S M
Publicado 2017

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer

por Hartmaier, R J, Trabucco, S E, Priedigkeit, N, Chung, J H, Parachoniak, C A, Vanden Borre, P, Morley, S, Rosenzweig, M, Gay, L M, Goldberg, M E, Suh, J, Ali, S M, Ross, J, Leyland-Jones, B, Young, B, Williams, C, Park, B, Tsai, M, Haley, B, Peguero, J, Callahan, R D, Sachelarie, I, Cho, J, Atkinson, J M, Bahreini, A, Nagle, A M, Puhalla, S L, Watters, R J, Erdogan-Yildirim, Z, Cao, L, Oesterreich, S, Mathew, A, Lucas, P C, Davidson, N E, Brufsky, A M, Frampton, G M, Stephens, P J, Chmielecki, J, Lee, A V
Publicado 2018